Sign up for the QMED & MD+DI Daily newsletter.
December 18, 2023
3 Min Read
Tomohiro Ohsumi / Getty Images News via Getty Images
Nab the Apple Watch Series 9 or Ultra 2 while you still can. After 3pm eastern standard time on Dec. 21, the tech giant said it is preemptively halting sales of the devices to the United States, with in-store inventory available until Dec. 24.
The announcement comes after the International Trade Commission (ITC) ruled in October to uphold a judge’s previous decision that found Apple had violated rights held by Masimo, a medtech company, in light-based technology for reading blood-oxygen levels. In litigation that began in 2020, Masimo alleged the company stole its intellectual property and incorporated it in several Apple Watch models.
The October ruling in Masimo’s favor did not immediately take effect to bar Apple Watch sales to the US market. Instead, the decision is currently facing a 60-day presidential review and possible appeals. The Biden Administration’s review period expires on Dec. 25, and an answer must be provided.
Of note, presidents have rarely vetoed bans in the past. One of the rare occasions in which a president decided to veto such a ban was in 2013. In that instance, President Barack Obama vetoed a ban on iPhones as part of Apples extended litigation will Samsung.
After the review period, Apple also has the opportunity to appeal the ban in the US Court of Appeals for the Federal Circuit after the review period ends.
Releasing a statement to 9to5Mac, Apple confirmed the news as it waits for the Biden Administrations decision, stating that if the decision stands, the company will pursue all available measures to return the watches affected to the US market.
“A Presidential Review Period is in progress regarding an order from the U.S. International Trade Commission on a technical intellectual property dispute pertaining to Apple Watch devices containing the Blood Oxygen feature. While the review period will not end until December 25, Apple is preemptively taking steps to comply should the ruling stand. This includes pausing sales of the Apple Watch Series 9 and Apple Watch Ultra 2 from Apple.com starting December 21, and from Apple retail locations after December 24,” according to the statement. “Apple’s teams work tirelessly to create products and services that empower users with industry-leading health, wellness, and safety features. Apple strongly disagrees with the order and is pursuing a range of legal and technical options to ensure that Apple Watch is available to customers. Should the order stand, Apple will continue to take all measures to return Apple Watch Series 9 and Apple Watch Ultra 2 to customers in the US as soon as possible.”
Currently, the ITC decision only prohibits Apple from selling the Series 9 and Ultra 2 models because both devices offer blood-oxygen monitoring capabilities. The Apple SE, which does not include the sensor, will remain unaffected and available for sale. Additionally, before the Dec. 25 cut off, the ruling only prohibits Apple from selling affected models, meaning that until the deadline, devices will remain available from other outlets like Amazon and Best Buy. If the decision is upheld by the president, after Dec. 25 all imports of those devices will be blocked from the US, and the company would be prohibited from selling them to resellers.
For current Series 9 and Ultra 2 model owners, the ITC order has made an exception to the ban for the service, repair, or warranty period of devices sold before the cut off.
In report from BTIG, analysts Marie Thibault and Sam Eiber digested the news, and deferred to previous discussions with patent attorney John Presper, Counsel for Foster Murphy Altman & Nicke, PC, who postulated that the most likely outcome will be that the administration takes no action to prevent the ban.
The analysts also raised questions regarding the potential for Masimo to bring forward additional litigation to obtain monetary reparations and royalties.
“If the review period ends without any presidential action, then the orders would go into effect immediately,” the analysts wrote. “We think there remains potential for [Masimo] to secure settlements, royalty payments, or other monetary-based agreements.”
About the Author(s)
Managing Editor, MD+DI
Katie Hobbins is managing editor for MD+DI and joined the team in July 2022. She boasts multiple previous editorial roles in print and multimedia medical journalism, including dermatology, medical aesthetics, and pediatric medicine. She graduated from Cleveland State University in 2018 with a bachelor's degree in journalism and promotional communications. She enjoys yoga, hand embroidery, and anything DIY. You can reach her at [email protected].
You May Also Like
Safeguard Medical Devices: A Complete Approach to Device Lifecycle SecurityApr 4, 2024|13:00 EDT
Top 40 Medical Device CompaniesFeb 29, 2024|2 Min Read
2024 Planning Guide for Medical Manufacturing AutomationFeb 29, 2024|1 Min Read
Wintriss to Display Production Tracking Software & other Supplier NewsFeb 28, 2024|3 Slides